Kymera Therapeutics Reports $34.4M Collaboration Revenue and $69.2M Net Loss in Q1 2026

Kymera Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a collaboration revenue of $34.4 million, a significant increase from $22.1 million in the same period last year. This growth is attributed to the company's collaboration agreement with Gilead Sciences, which has recently progressed to include a $45 million milestone payment following Gilead's exercise of its option to license a novel oral CDK2 molecular glue degrader, KT-200. Despite the increase in revenue, Kymera's operating expenses also rose, totaling $118.5 million compared to $96.5 million in the prior year, primarily driven by higher research and development costs.

The company's net loss for the quarter was $69.2 million, slightly higher than the $65.6 million loss reported in the first quarter of 2025. The increase in losses was influenced by a rise in research and development expenses, which reached $98.2 million, up from $80.3 million a year earlier. This increase reflects Kymera's ongoing investment in its clinical programs, particularly in the STAT6 program, which saw a $12.6 million increase in costs. General and administrative expenses also rose to $20.4 million from $16.3 million, driven by higher legal and professional service fees.

As of March 31, 2026, Kymera's total assets amounted to $1.67 billion, a decrease from $1.74 billion at the end of 2025. The decline in total assets was primarily due to a reduction in cash and cash equivalents, which fell to $144.1 million from $357 million. The company reported an accumulated deficit of $1.14 billion, reflecting its ongoing investment in research and development without yet generating product sales. Kymera's cash, cash equivalents, and marketable securities totaled $1.55 billion, which management believes will be sufficient to fund operations through at least 2029.

In terms of operational developments, Kymera has made significant strides in its clinical programs, with ongoing trials for its STAT6 and IRAK4 programs. The company is also exploring additional collaborations to enhance its pipeline. As part of its strategic initiatives, Kymera has focused on expanding its research capabilities and advancing its drug development efforts. The company anticipates that its expenses will continue to rise as it progresses through clinical trials and prepares for potential commercialization of its product candidates.

Looking ahead, Kymera remains committed to its goal of developing innovative therapies for patients with significant unmet medical needs. The company plans to leverage its existing cash reserves and potential future collaborations to support its research and development activities. However, it acknowledges the inherent risks and uncertainties in drug development, including the need for substantial additional funding to achieve its long-term objectives.